At Gertrude Biomedical, our strategy is focussed on the control of abnormal vascular growth by targeting the key gene 'switches' (known as transcription factors) that turn blood vessel formation 'on or off' in human disease.
Gertrude Biomedical’s aim is to develop drug treatments that effectively combat otherwise poorly treated diseases, related to abnormal blood vessel growth.
The Gertrude Biomedical team combines expertise in vascular and SOX18 biology, medicinal chemistry, drug discovery, development and commercialisation, and the clinical treatment of important vascular-related diseases.
